

Dr. Oliver Kisker, MD, PhD

Dr. Oliver Kisker, MD, PhD, is currently Global Head of the Global Clinical Development Unit (GCDU) Oncology at Merck Serono.

He joined Merck in 2002 as the leading physician for Cilengitide and Erbitux. In 2004 he became the Global Head of EGFR Programs and in 2007 the Global Head of EGFR and Angiogenesis inhibitors in the GCDU Oncology.

He is Assistant Professor in the surgical department at Philipps-University Marburg, Germany since 2004 and has 10 years clinical and academic research experience in surgical oncology and molecular and cell-biology.

He is a member of American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and the Germany Society for Surgery.

After graduating from medical school Dr Kisker went on to join the surgical department at Philipps-University Marburg.

From 1997 until 2000, Dr Kisker was principal investigator at the department of surgical research, Harvard Medical School, Boston, researching angiogenesis inhibitors in pancreatic carcinoma and working under Prof. Dr. Judah Folkman.

He has published more than 30 scientific articles within journals such as Nature, Cancer Cell and Cancer Research and has won awards for research from the American Association of Cancer Research, the International Society of Surgery and the GINo-Innovations Award.

